140 related articles for article (PubMed ID: 31844143)
21. A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia.
Pemmaraju N; Kantarjian H; Kadia T; Cortes J; Borthakur G; Newberry K; Garcia-Manero G; Ravandi F; Jabbour E; Dellasala S; Pierce S; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):171-6. PubMed ID: 25441108
[TBL] [Abstract][Full Text] [Related]
22. ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia.
Elliott MA; Pardanani A; Hanson CA; Lasho TL; Finke CM; Belachew AA; Tefferi A
Am J Hematol; 2015 Jul; 90(7):653-6. PubMed ID: 25850813
[TBL] [Abstract][Full Text] [Related]
23. Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study.
Naqvi K; Daver N; Pemmaraju N; Bose P; Garcia-Manero G; Cortes J; Kantarjian HM; Verstovsek S
Leuk Lymphoma; 2017 Apr; 58(4):866-871. PubMed ID: 27494751
[TBL] [Abstract][Full Text] [Related]
24. Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition.
Raab MS; Lehners N; Xu J; Ho AD; Schirmacher P; Goldschmidt H; Andrulis M
Blood; 2016 Apr; 127(17):2155-7. PubMed ID: 26884375
[No Abstract] [Full Text] [Related]
25. Ibrutinib for Chronic Lymphocytic Leukemia with
Ahn IE; Tian X; Wiestner A
N Engl J Med; 2020 Jul; 383(5):498-500. PubMed ID: 32726539
[No Abstract] [Full Text] [Related]
26. Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management.
Szuber N; Elliott M; Tefferi A
Am J Hematol; 2020 Feb; 95(2):212-224. PubMed ID: 31769070
[TBL] [Abstract][Full Text] [Related]
27. Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status.
Schmidt M; Rinke J; Schäfer V; Schnittger S; Kohlmann A; Obstfelder E; Kunert C; Ziermann J; Winkelmann N; Eigendorff E; Haferlach T; Haferlach C; Hochhaus A; Ernst T
Leukemia; 2014 Dec; 28(12):2292-9. PubMed ID: 25212276
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): case report.
Choi IK; Kim BS; Lee KA; Ryu S; Seo HY; Sul H; Choi JG; Sung HJ; Park KH; Yoon SY; Oh SC; Seo JH; Choi CW; Shin SW; Yoon SY; Cho Y; Kim YK; Kim YH; Kim JS
Am J Hematol; 2004 Dec; 77(4):366-9. PubMed ID: 15551277
[TBL] [Abstract][Full Text] [Related]
29. Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis.
Langabeer SE; Haslam K; Kelly J; Quinn J; Morrell R; Conneally E
Clin Transl Oncol; 2018 Mar; 20(3):420-423. PubMed ID: 28762112
[TBL] [Abstract][Full Text] [Related]
30. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation.
Newberry KJ; Patel K; Masarova L; Luthra R; Manshouri T; Jabbour E; Bose P; Daver N; Cortes J; Kantarjian H; Verstovsek S
Blood; 2017 Aug; 130(9):1125-1131. PubMed ID: 28674026
[TBL] [Abstract][Full Text] [Related]
31. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.
Woyach JA
Clin Adv Hematol Oncol; 2016 May; 14(5):330-3. PubMed ID: 27379693
[No Abstract] [Full Text] [Related]
32. Jak-2 positive myeloproliferative neoplasms.
Muxí PJ; Oliver AC
Curr Treat Options Oncol; 2014 Jun; 15(2):147-56. PubMed ID: 24627006
[TBL] [Abstract][Full Text] [Related]
33. Chronic neutrophilia associated with myeloma: is it clonal?
Nedeljkovic M; He S; Szer J; Juneja S
Leuk Lymphoma; 2014 Feb; 55(2):439-40. PubMed ID: 23713456
[No Abstract] [Full Text] [Related]
34. Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management.
Elliott MA; Tefferi A
Am J Hematol; 2018 Aug; 93(4):578-587. PubMed ID: 29512199
[TBL] [Abstract][Full Text] [Related]
35. Real-world results of ibrutinib in relapsed/refractory CLL in France: Early results on a large series of 428 patients.
Ysebaert L; Aurran-Schleinitz T; Dartigeas C; Dilhuydy MS; Feugier P; Michallet AS; Tournilhac O; Dupuis J; Sinet P; Albrecht C; Cymbalista F
Am J Hematol; 2017 Aug; 92(8):E166-E168. PubMed ID: 28439916
[No Abstract] [Full Text] [Related]
36. Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL.
Eskelund CW; Husby S; Favero F; Klausen TW; Rodriguez-Gonzalez FG; Kolstad A; Pedersen LB; Räty RK; Geisler CH; Jerkeman M; Weischenfeldt J; Grønbæk K
Blood; 2020 May; 135(22):2000-2004. PubMed ID: 32181815
[No Abstract] [Full Text] [Related]
37. Efficacy and safety of ruxolitinib after and versus interferon use in the RESPONSE studies.
Kiladjian JJ; Guglielmelli P; Griesshammer M; Saydam G; Masszi T; Durrant S; Passamonti F; Jones M; Zhen H; Li J; Gadbaw B; Perez Ronco J; Khan M; Verstovsek S
Ann Hematol; 2018 Apr; 97(4):617-627. PubMed ID: 29396713
[TBL] [Abstract][Full Text] [Related]
38. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia.
Eghtedar A; Verstovsek S; Estrov Z; Burger J; Cortes J; Bivins C; Faderl S; Ferrajoli A; Borthakur G; George S; Scherle PA; Newton RC; Kantarjian HM; Ravandi F
Blood; 2012 May; 119(20):4614-8. PubMed ID: 22422826
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis.
Arana Yi C; Tam CS; Verstovsek S
Future Oncol; 2015; 11(5):719-33. PubMed ID: 25757677
[TBL] [Abstract][Full Text] [Related]
40. Ibrutinib-Induced Lymphocytosis: Cytological Features.
Quintela A; Sujobert P; Callet-Bauchu E; Salles G; Baseggio L
Acta Haematol; 2017; 137(1):55-57. PubMed ID: 27960168
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
